Cna Financial Corp Revance Therapeutics, Inc. Transaction History

Cna Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$12.46 - $27.87 $230,634 - $515,873	-18,510 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $36,349 - $46,826	1,410 Added 8.25%	18,510 $516,000
Q2 2021 Aug 12, 2021	SELL	$26.8 - $31.84 $72,360 - $85,968	-2,700 Reduced 13.64%	17,100 $507,000
Q1 2021 May 14, 2021	BUY	$24.03 - $29.97 $41,091 - $51,248	1,710 Added 9.45%	19,800 $553,000
Q4 2020 Feb 12, 2021	BUY	$23.41 - $28.34 $91,299 - $110,526	3,900 Added 27.48%	18,090 $513,000
Q3 2020 Nov 12, 2020	SELL	$23.23 - $34.3 $33,683 - $49,734	-1,450 Reduced 9.27%	14,190 $357,000
Q2 2020 Aug 13, 2020	BUY	$12.6 - $26.55 $197,064 - $415,242	15,640 New	15,640 $382,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.